2019 May – 2021 Apr

Development of an ex-vivo transmission blocking assay for clinical isolates of matured Plasmodium falciparum gametocytes through membrane feeding assays African Academy of Science (AAS), University of Sciences, Techniques and Technologies of Bamako (USTTB), Mali | Dinkorma Ouologuem | Africa, Central, Africa, Eastern, Africa, Southern, Mali

Similar Posts

  • PYRAPREG

    Malaria in pregnant is a public health problem in sub Saharan countries where 11 million pregnancies are exposed to malaria infection. Plasmodium falciparum in pregnant can cause adverse maternal health and poor birth outcomes. Artemisin-based Combination Therapy (ACT) used in treatment of uncomplicated Plasmodium falciparum malaria in pregnant women has the efficacy in Africa. The…

  • DELGEME

    The Developing Excellence in Leadership and Genetics Training for Malaria Elimination in sub-Saharan Africa (DELGEME) is a training programme sponsored by the Wellcome Trust Developing Excellence in Leadership, Training and Science Africa (DELTAS Africa) initiative in partnership with the Department of International Development (DFID) and the Alliance for Accelerating Excellence in Science in Africa (AESA). …

  • 2016 Dec – 2022 Dec | 1 subproject

    Proactive Community Case Management and Child Survival: A Cluster-Randomized Controlled Trial Child Relief International Foundation, Grand Challenges Canada, Johnson & Johnson Foundation, United States Agency for International Development (USAID), University of California San Francisco (UCSF), USA, Malaria Research and Training Center (MRTC), University of Bamako, Mali | Kassoum Kayentao, Nancy S. Padian | Mali

  • WANECAM

    WANECAM is the West African Network for Clinical Trials of Antimalarial drugs. This network is being supported by grants from the European & Developing Countries Clinical Trials Partnership (EDCTP). The WANECAM 2 project aims to accelerate the development of the  Ganaplacide/lumefantrine  combination for the treatment of uncomplicated malaria by conducting clinical trials in four countries…

Leave a Reply

Your email address will not be published. Required fields are marked *